CClinicalTrials.gg
CompletedNCT00838331INOBAUpdated Mar 6, 2015Results posted

Adverse Effects of RBC Transfusions: A Unifying Hypothesis

A Phase 2 interventional study of Fresh blood and Aged blood in Healthy Volunteers, sponsored by Emory University. Completed at 1 site in United States. Open to participants aged 21 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-03-06.

Sponsored by Emory University · Phase 2, Interventional, and Treatment

Phase
Phase 2
Study type
Interventional
Enrollment
24
Allocation
Not applicable
Ages
21 Years to 80 Years
Sex
All
01

Study summary

Transfusion of red blood cells is often used in critically ill patients with low red blood cell counts to prevent disease progression and death. Recent studies suggest that the use of "aged" versus "fresh" red blood cells are associated with worse clinical outcomes. There is evidence that red blood cells work with the cells lining our blood vessels to produce a variety of substances that normally cause arteries to relax and increase blood supply. Two of these substances are called nitric oxide (NO) and endothelium-derived hyperpolarizing factor (EDHF). The investigators are trying to determine the nature of these substances in human beings when they are transfused "aged" versus "fresh" red blood cells. It is their thought that "aged" red blood cells have less of the substances (NO and EDHF) that naturally relax our arteries and further changes the blood supply. One way to determine this is to transfuse a subject's own "aged" and "fresh" red blood cells and inject substances such as L-NMMA (L-NG monomethyl arginine) and TEA (tetraethylammonium chloride), which block the production of NO and EDHF respectively, and then, study what happens to the blood flow.

There is evidence that red blood cells produce NO, which normally causes arteries to relax and increase blood supply. The investigators will try to determine the nature of NO in red blood cells and whether the amount of this substance is altered because of different blood processing and storage techniques. It is their thought that "aged" red blood cells have less NO that naturally relaxes our arteries and further changes the blood supply. This study is designed to determine the most ideal way of storing and processing blood.

Read the detailed description

Transfusion of red blood cells (RBCs) is often effective at preventing morbidity and mortality in anemic patients. In contrast, recent studies indicate that some RBC components may have functional defects ("RBC storage lesions") that actually cause morbidity and mortality when transfused. For example, patients transfused with RBCs stored >14 days have statistically worse outcomes than those receiving "fresher" RBC units. In addition to the age of stored RBCs, the volume transfused may be important. The TRICC study showed that specific patients whose transfusions were limited by a restrictive trigger (RBCs transfusions only when hemoglobin [Hb] \< 7 g/dL) had significantly better outcomes than those transfused with a more liberal trigger ([Hb] \< 10 g/dL Hb). This finding has been particularly difficult to understand since conventional wisdom suggests that an elevated [Hb] should be beneficial because it supports increased O2 delivery. Recipient-specific factors may also contribute to the occurrence of these adverse events. Unfortunately, these events have been difficult to investigate because up to now they have existed only as "statistical occurrences" of increased morbidity and mortality in large data sets. There are currently no clinical or laboratory methods to detect or study them in individual patients.

The microcirculation is composed of a continuum of small vessels including small arterioles, capillaries, and post-capillary venules. The microcirculation represents an actively-adjusting vascular circuit that matches blood flow (and O2 delivery) to local tissue oxygen demands. While the physiologic mechanisms that match O2 delivery to local requirements are incompletely understood, endothelium-derived nitric oxide (NO) clearly plays an important role. Interestingly, recent work has revealed that in addition to transporting O2 and CO2, the RBC also controls local NO concentrations and thus may also play a surprisingly important role in regulating blood flow in the microcirculation.

Herein, the investigators bring together previously unconnected data to propose a unifying hypothesis, centered on insufficient NO bioavailability (INOBA), to explain the increased morbidity and mortality observed in some patients following RBC transfusion. In this model, variables associated with RBC units (storage time; 2,3-DPG concentration) and transfusion recipients (endothelial dysfunction; hematocrit [Hct]) collectively lead to changes in NO levels in vascular beds. Under certain circumstances, these variables are "aligned" such that NO concentrations are markedly reduced, leading to vasoconstriction, decreased local blood flow and insufficient O2 delivery to end organs. Under these circumstances, the likelihood of morbidity and mortality escalates. The INOBA hypothesis is attractive because of its explanatory power and because it leads to a number of readily testable predictions, which will be investigated in the following aims:

Aim 1: To investigate the effects of blood processing and storage (using standard FDA-approved conditions) on NO production and scavenging by human RBCs/Hb in vitro. Using sensitive biochemical assays (electron spin resonance [ESR]) and a rat aortic ring in vitro bioassay, the investigators will test the effects of RBC storage time, leukoreduction, and irradiation on NO synthesis and/or scavenging by intact RBCs and free Hb. Modifications such as washing and rejuvenation will be investigated as possible approaches to correct abnormalities in NO bioavailability.

Aim 2: To transfuse healthy volunteers and investigate the effects of storage-related RBC changes on blood flow, tissue oxygenation, and biomarkers of cardiovascular function. The investigators will determine whether RBCs prepared and stored under conditions that alter NO bioavailability in vitro (Aim 1) inhibit NO-mediated vasodilation, reduce tissue perfusion, and decrease tissue O2 delivery in healthy transfusion recipients in vivo. The role of 2,3-DPG depletion as well as exercise-induced O2 demand will also be investigated with these specialized experimental systems.

02

Conditions studied

  • Healthy Volunteers

Keywords

  • Blood Transfusions
03

In context

Lead sponsor

Emory University is the lead sponsor of 1,386 studies on the registry; 236 are open to participants now.

Of its 229 completed or terminated interventional studies of FDA-regulated products, 174 (76%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Aim 1:

Inclusion Criteria:

  • Healthy male or female volunteers (age 21-60 years)

Must meet guidelines for blood donors including:

  • standard blood donor history questionnaire
  • body weight of at least 110 lbs
  • hemoglobin concentration of at least 12.5 gm/dL
  • body temperature of no more than 99.5 oF
  • pulse of 50-100 bpm
  • blood pressure \< 180/100
  • test negative for the standard battery of blood donor screening tests (anti-HIV, HIV RNA, anti-HCV, HCV RNA, HBsAg, anti-HBc, anti-HTLV-I/II, and WNV RNA)

Aim 1:

Exclusion Criteria:

  • Failure to pass the blood donor history questionnaire
  • Positive results on the standard battery of blood donor screening tests
  • Failure to meet criteria for donation

Aim 2:

Inclusion Criteria:

  • Healthy male or female volunteers (age 21-80 years)

Exclusion Criteria:

  • Presence of intercurrent illness or other chronic diseases
  • Renal failure (creatinine>1.4 mg/dl)
  • Pregnancy
  • Allergies to aspirin
  • Bleeding disorders
  • Uncontrolled hypertension with BP > 180 mmHg systolic and > 120 mmHg diastolic
  • Acute infection in previous 4 weeks
  • History of substance abuse
  • Liver failure (Liver enzymes >2x normal)
  • Inability to give informed consent
  • Inability to return to Emory for follow-up
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Fresh blood, then aged blood

    Biological: Fresh blood · Biological: Aged blood

Interventions

  • BiologicalFresh blood

    For fresh transfusions, a whole blood unit will be drawn from volunteers, processed, and then reinfused on the same day during the study. For impaired and repaired transfusions, the volunteers will be brought to the blood bank to donate; then, after processing and the appropriate length of storage (eg, 28 days), they will return for the FBF studies. Since recipients of fresh transfusions are relatively anemic after donation and before reinfusion, recipients of impaired/repaired transfusions should also be mildly anemic for the study. Thus, they will donate another whole blood unit prior to beginning the study course, they will be transfused with their stored unit during the study, and then the autologous unit collected at the beginning of the day will be reinfused at the end of the day after the study is complete.

  • BiologicalAged blood

    In a separate aim, the FMD assay will be used to investigate NO-mediated vasodilation in patients with CVD who are receiving transfusions. Over 60% of blood orders for cardiology patients at Emory are for 2 units or more. Therefore, when a 2-unit order is placed on a consented patient, they will be issued both fresh (\< 7 days) and impaired (\> 28 days) compatible units from inventory. Prior to starting transfusions, the patient will be randomized to either receive the fresh or the older unit first. All RBC units will be ACD/AS1. Units will also be leukoreduced and/or irradiated, if either of those modifications were found to impair NO bioavailability in prior studies. If washing or rejuvenation were found to be successful in significantly "repairing" NO bioavailability in previous aims, some patients may also receive impaired and repaired (\> 28 days; washed or rejuvenated) RBC transfusions.

06

What researchers measure

Primary outcomes

  1. The Effects of Storage-related RBC Changes on Acetylcholine-stimulated (NO-mediated) Forearm Blood Flow.

    The primary outcome measures are changes in forearm blood flow (FBF) in recipients of fresh or stored RBC transfusions in response to acetylcholine. Secondary measures include changes in FBF with acetylcholine with or without L-NMMA, and changes in FBF with forearm exercise. In addition, flow mediated dilation (FMD) measurements will also be used to assess changes in brachial artery diameter before and after fresh vs aged RBC transfusions.

    Time frame: 5 years

07

Results

Posted Mar 6, 2015
Limitations and caveats
Primary limitation is that we are studying transfusion effects of fresh vs stored RBCs in healthy individuals, and not sick, anemic individuals as are often encountered in the hospital.

Participant flow

Fresh Blood Transfusion
Participant flow — Fresh Blood Transfusion
MilestoneFresh Blood, Then Aged Blood
Started17
Completed17
Not completed0
Aged Blood Transfusion
Participant flow — Aged Blood Transfusion
MilestoneFresh Blood, Then Aged Blood
Started17
Completed8
Not completed9
Withdrew: Withdrawal by subject9

Outcome measures

PrimaryThe Effects of Storage-related RBC Changes on Acetylcholine-stimulated (NO-mediated) Forearm Blood Flow.

The primary outcome measures are changes in forearm blood flow (FBF) in recipients of fresh or stored RBC transfusions in response to acetylcholine. Secondary measures include changes in FBF with acetylcholine with or without L-NMMA, and changes in FBF with forearm exercise. In addition, flow mediated dilation (FMD) measurements will also be used to assess changes in brachial artery diameter before and after fresh vs aged RBC transfusions.

Time frame:
5 years
Reported as:
Mean · mL / 100 mL / min
The Effects of Storage-related RBC Changes on Acetylcholine-stimulated (NO-mediated) Forearm Blood Flow.
mL / 100 mL / minFresh Blood, Then Aged Blood
Prior to transfusion; fresh blood19.02 ± 8.22
Prior to transfusion; aged blood18.42 ± 4.73
Immediately after transfusion; fresh blood17.61 ± 4.8
Immediately after transfusion; aged blood22.89 ± 5.52
24 hours after transfusion; fresh blood22.83 ± 19.66
24 hours after transfusion; aged blood19.66 ± 3.62

Adverse events

Collected over Within 6 months of the start of the study.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
All Subjects—0/17 (0%)0/17 (0%)

Baseline characteristics

Only the 8 volunteers who completed both arms of this study are analyzed here.

Age, Categorical
Age, Categorical(Participants)All Subjects
<=18 years0
Between 18 and 65 years8
>=65 years0
Age, Continuous
Age, Continuous(years)All Subjects
Mean26.6 ± 3.4
Sex: Female, Male
Sex: Female, Male(Participants)All Subjects
Female3
Male5
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)All Subjects
Caucasian4
African-American1
Asian-American2
"Other"1
Region of Enrollment
Region of Enrollment(participants)All Subjects
United States8
08

Study locations

1 site
  • Emory University
    Atlanta, Georgia 30322, United States
09

References and documents

Publications

  • Hayek SS, Neuman R, Ashraf K, Sher S, Newman JL, Karatela S, Roback JD, Quyyumi AA. Effect of storage-aged red blood cell transfusions on endothelial function in healthy subjects. Transfusion. 2015 Nov;55(11):2768-70. doi: 10.1111/trf.13276. No abstract available. PubMed 26559401 ↗
  • Neuman R, Hayek S, Rahman A, Poole JC, Menon V, Sher S, Newman JL, Karatela S, Polhemus D, Lefer DJ, De Staercke C, Hooper C, Quyyumi AA, Roback JD. Effects of storage-aged red blood cell transfusions on endothelial function in hospitalized patients. Transfusion. 2015 Apr;55(4):782-90. doi: 10.1111/trf.12919. Epub 2014 Nov 13. PubMed 25393772 ↗
10

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 6, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00838331
Lead sponsor
Emory University
Responsible party
John D Roback (Professor, Emory University) — Principal investigator
First posted
Feb 6, 2009
Start date
Apr 2009
Primary completion
May 2013
Completion
Oct 2013
Results posted
Mar 6, 2015
Last update
Mar 6, 2015

Study contacts

Arshed A Quyyumi, MD
principal investigator · Emory University
John Roback, MD, PhD
principal investigator · Emory University

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion